Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.

This study has identified molecular changes characteristic of early oral cancer progression. We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886-3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and this is associated with loss of expression of retinoic acid receptor (RAR)-beta and the cell cycle inhibitor p16(ink4a) (p16), p53 mutations, and increased levels of telomerase/human telomerase reverse transcriptase mRNA. In contrast, increased expression of the epidermal growth factor receptor, known to be a characteristic of oral cancer, does not occur until after the dysplasia stage in squamous cell carcinomas. Acquisition of invasive properties as judged by an in vitro Matrigel invasion assay also does not occur until the carcinoma stage and is further increased in metastases. Interestingly, one atypical mortal dysplasia with a considerably extended life span has lost expression of RAR-beta and p16, but it still expresses only wild-type p53 (albeit at a higher level than normal) and has not activated telomerase. RAR-beta and/or p16 re-expression can be induced by treatment with 5-aza-2-deoxycytidine (Aza-C) in some immortal dysplasias, and this has been shown to be due to silencing of gene expression by promoter methylation. Aza-C treatment also down-regulated telomerase activity and human telomerase reverse transcriptase mRNA. Interestingly, with one dysplasia, Aza-C was able to reverse its immortal phenotype, as judged by morphological criteria and expression of the senescence-associated acid beta-galactosidase activity during terminal growth arrest; this immortal dysplasia was the only one in which Aza-C treatment not only down-regulated telomerase activity but also induced re-expression of both RAR-beta and p16. The possibility of reversing the immortal phenotype of some dysplasias by Aza-C may be of clinical usefulness.

[1]  D. Hanahan.  Cancer: Benefits of bad telomeres , 2000, Nature.

[2]  A. Franchi,et al.  Cumulative prognostic value of p16/CDKN2 and p53 oncoprotein expression in premalignant laryngeal lesions. , 1997, Journal of the National Cancer Institute.

[3]  S. Lippman,et al.  Frequent inactivation of p16INK4a in oral premalignant lesions , 1997, Oncogene.

[4]  L. Gaboury,et al.  Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4‐like transgene. , 1994, The EMBO journal.

[5]  J. Campisi.  Cancer, aging and cellular senescence. , 2000, In vivo.

[6]  D. Soutar,et al.  Inappropriate retinoic acid receptor-beta expression in oral dysplasias: correlation with acquisition of the immortal phenotype. , 1997, Cancer research.

[7]  G. Peters,et al.  Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. , 1999, Cancer research.

[8]  P. Chambon,et al.  Differentially expressed isoforms of the mouse retinoic acid receptor beta generated by usage of two promoters and alternative splicing. , 1991, The EMBO journal.

[9]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.

[10]  W. Hahn,et al.  Human Keratinocytes That Express hTERT and Also Bypass a p16INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics , 2000, Molecular and Cellular Biology.

[11]  G. Peters,et al.  Role of the Alternative INK 4 A Proteins in Human Keratinocyte Senescence : Evidence for the Specific Inactivation of p 16 INK 4 A upon Immortalization 1 , 2000 .

[12]  P. Chambon,et al.  Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. , 1991, Cancer research.

[13]  R. Lotan,et al.  Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. , 1994, Cancer research.

[14]  S. Lippman,et al.  Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[16]  Xu-Rong Jiang,et al.  Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype , 1999, Nature Genetics.

[17]  J. Minna,et al.  ACCELERATED DISCOVERY Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas , 2000 .

[18]  M. Nikolic,et al.  Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. , 1994, British Journal of Cancer.

[19]  J. Bartek,et al.  High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. , 1996, Cancer research.

[20]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[21]  J. McDougall,et al.  Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. , 2000, The American journal of pathology.

[22]  F. Bosman,et al.  Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. , 1999, Blood.

[23]  R. Iggo,et al.  High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay , 1997, Oncogene.

[24]  M. Stanley,et al.  Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. , 1996, Oncogene.

[25]  J. Shay,et al.  Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. , 2001, Genes & development.

[26]  M. Symons,et al.  The Transcription Factor AP-1 Is Required for EGF-induced Activation of Rho-like GTPases, Cytoskeletal Rearrangements, Motility, and In Vitro Invasion of A431 Cells , 1998, The Journal of cell biology.

[27]  S. Lippman,et al.  p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma , 1996 .

[28]  E. K. Parkinson,et al.  The p53 status of cultured human premalignant oral keratinocytes. , 1994, British Journal of Cancer.

[29]  E. Parkinson,et al.  Cellular immortality: A late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss , 1995, Molecular carcinogenesis.

[30]  Young-Hwa Song,et al.  Identification of Mad as a repressor of the human telomerase (hTERT) gene , 2000, Oncogene.

[31]  J. Bartek,et al.  Aberrant p21CIP1/WAF1 protein accumulation in head‐and‐neck cancer , 1997 .

[32]  R. Medema,et al.  Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[33]  N D Le,et al.  Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  L. Chin,et al.  Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation , 1999, Oncogene.

[35]  K. Wiman,et al.  Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells , 2000, Oncogene.

[36]  J. Bartek,et al.  Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. , 1997, International journal of cancer.

[37]  F. Bosman,et al.  Frequent Methylation Silencing of p 15 INK 4 b ( MTS 2 ) and p 16 INK 4 a ( MTS 1 ) in B-Cell and T-Cell Lymphomas , 1999 .

[38]  S. Kyo,et al.  Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  M. Dictor,et al.  Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. , 2000, Cancer.

[40]  B. Houle,et al.  Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Lynda Chin,et al.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice , 2000, Nature.

[42]  F. Shepherd,et al.  Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. , 1999, Cancer research.

[43]  J. Rheinwald,et al.  Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. , 1981, Cancer research.

[44]  P. Hall,et al.  The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[45]  D. Tweardy,et al.  Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[47]  H. Tsou,et al.  Down-Regulation of Retinoic Acid Receptor 3 in Mammary Carcinoma Cell Lines and Its Up-Regulation in Senescing Normal Mammary Epithelial Cells 1 , 2005 .

[48]  R. Reddel,et al.  p16(INK4a) and the control of cellular proliferative life span. , 1999, Carcinogenesis.

[49]  C. von Ilberg,et al.  Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[50]  Y. Fujiwara.  [Aging and cellular senescence]. , 1995, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[51]  E. Dmitrovsky,et al.  Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. , 1999, Cancer research.

[52]  R. Sutherland,et al.  Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  J. Grandis,et al.  Retinoic acid normalizes the increased gene transcription rate of TGF–α and EGFR in head and neck cancer cell lines , 1996, Nature Medicine.

[54]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[55]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[56]  B. Houle,et al.  RARbeta2 specificity in mediating RA inhibition of growth of lung cancer-derived cells. , 2000, Lung cancer.

[57]  S. Lippman,et al.  Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  H. Saya,et al.  Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx , 2000, International journal of cancer.

[59]  J. Grandis,et al.  Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. , 1998, International journal of oncology.

[60]  R. Kothary,et al.  Lung tumors in mice expressing an antisense RARβ2 transgene , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  R. Maestro,et al.  Overexpression of CDC25A and CDC25B in head and neck cancers. , 1997, Cancer research.

[62]  A. Klein-Szanto,et al.  Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  P. Burns,et al.  Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. , 1977, British Journal of Cancer.

[64]  R. Reddel,et al.  Telomere maintenance mechanisms and cellular immortalization. , 1999, Current opinion in genetics & development.

[65]  A. El‐Naggar,et al.  PRAD‐1 (CCND1)/Cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma , 1994, Cancer.

[66]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.